aesPlla is a next-generation biostimulatory injectable combining well-established biomaterials with a carefully balanced formulation. Rather than providing immediate volume correction, it works within the skin to support gradual structural improvement and a natural-looking aesthetic outcome.
Key components:
- Poly-L-Lactic Acid (PLLA)
A biodegradable polymer widely used in aesthetic medicine. PLLA microparticles are known to stimulate collagen synthesis over time, contributing to improved skin firmness and texture.
- Sodium Carboxymethylcellulose
A polysaccharide that functions as a stabiliser and thickening agent, supporting homogeneous suspension and even distribution of PLLA particles after reconstitution.
- Mannitol
An antioxidant used to help protect the formulation from oxidative processes and to support product stability. It is also commonly used to reduce the risk of swelling following injection.
All components are biocompatible and biodegradable. The PLLA microparticles are gradually broken down and metabolised by the body over time, without permanent accumulation in the tissue.
aesPlla is CE-certified as a medical device and complies with applicable European quality and safety standards.
aesPlla is designed to support skin quality improvement through collagen stimulation. Depending on the individual treatment plan, potential outcomes may include:
- improved skin firmness and elasticity
- smoother skin texture
- reduction in the appearance of fine lines and wrinkles
- overall refreshed and revitalised skin appearance
The product is commonly used in areas affected by age-related skin changes, such as:
- mid-face and cheeks
- lower face and jawline
- chin area
- periocular region
- neck and décolleté
- hands
- selected body areas (e.g. buttocks), depending on practitioner assessment
aesPlla is intended for subdermal and intradermal injection. A typical treatment protocol may include 2–3 sessions at intervals of approximately 5–6 weeks, depending on clinical assessment and individual response.
Results develop gradually and are not immediate. The duration and visibility of effects vary between patients.
For professional use only.
Each package of aesPlla Oreon Life Science contains one vial with 365 mg of sterile lyophilised powder, consisting of:
- Poly-L-Lactic Acid (PLLA): 150 mg
- Sodium Carboxymethylcellulose: 90 mg
- Mannitol: 125 mg
This product may only be administered by licensed and appropriately trained medical professionals in a suitable medical setting. This description is provided for informational purposes only and does not replace medical advice or professional training.